Which tool is used to assess alcohol withdrawal severity, and what is the typical treatment approach?

Which tool is used to assess alcohol withdrawal severity, and what is the typical treatment approach?

• A. MMSE.
• B. CIWA-Ar with benzodiazepine titration.
• C. PHQ-9.
• D. AUDIT-C.

Answer: (B)

Assessing how bad alcohol withdrawal is requires a scale that specifically captures withdrawal symptoms and their intensity. The standard tool for this is CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised). It measures multiple domains—autonomic symptoms (like sweating and pulse), tremors, agitation, anxiety, nausea/vomiting, perceptual disturbances, headaches, and orientation/think—and assigns a numerical score that tracks how withdrawal is evolving. The higher the score, the more aggressive the treatment needs to be to prevent progression to seizures or delirium tremens. The typical treatment approach uses benzodiazepines dosed and titrated based on the CIWA-Ar score. In practice, a benzodiazepine such as diazepam, chlordiazepoxide, or lorazepam is given and then adjusted up or down as the patient’s CIWA-Ar score changes, with frequent reassessment (often every 1–2 hours early on). The aim is to keep withdrawal in a mild range and taper off gradually to prevent rebound symptoms. Alongside this, thiamine is given to prevent Wernicke’s encephalopathy, and fluids/electrolytes are corrected as needed. If liver disease is a concern, a benzodiazepine with safer hepatic metabolism (like lorazepam) may be preferred. Other tools like MMSE, PHQ-9, or AUDIT-C assess cognitive function, depressive symptoms, or drinking patterns, but they do not quantify withdrawal severity, which is why CIWA-Ar with benzodiazepine titration is the standard approach.

Assessing how bad alcohol withdrawal is requires a scale that specifically captures withdrawal symptoms and their intensity. The standard tool for this is CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised). It measures multiple domains—autonomic symptoms (like sweating and pulse), tremors, agitation, anxiety, nausea/vomiting, perceptual disturbances, headaches, and orientation/think—and assigns a numerical score that tracks how withdrawal is evolving. The higher the score, the more aggressive the treatment needs to be to prevent progression to seizures or delirium tremens.

The typical treatment approach uses benzodiazepines dosed and titrated based on the CIWA-Ar score. In practice, a benzodiazepine such as diazepam, chlordiazepoxide, or lorazepam is given and then adjusted up or down as the patient’s CIWA-Ar score changes, with frequent reassessment (often every 1–2 hours early on). The aim is to keep withdrawal in a mild range and taper off gradually to prevent rebound symptoms. Alongside this, thiamine is given to prevent Wernicke’s encephalopathy, and fluids/electrolytes are corrected as needed. If liver disease is a concern, a benzodiazepine with safer hepatic metabolism (like lorazepam) may be preferred.

Other tools like MMSE, PHQ-9, or AUDIT-C assess cognitive function, depressive symptoms, or drinking patterns, but they do not quantify withdrawal severity, which is why CIWA-Ar with benzodiazepine titration is the standard approach.